Population Pharmacokinetics of Enoxaparin During the Antenatal Period
Open Access
- 24 September 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 128 (13), 1462-1469
- https://doi.org/10.1161/circulationaha.113.003198
Abstract
Background— The optimal dosing strategy of low-molecular-weight heparins for the treatment of antenatal venous thromboembolism is not known. The physiological changes associated with pregnancy alter the pharmacokinetic profile of low-molecular-weight heparins, which has led to controversy and subsequent variation in practice, when pregnant women with venous thromboembolism are treated with low-molecular-weight heparins. Our objective was to develop a robust pharmacokinetic model of enoxaparin during the antenatal period to address this problem. Method and Results— Women prescribed antenatal enoxaparin were eligible to enroll in the study. Recruited women were reviewed monthly and had up to 3 anti-Xa activities (trough and 1 and 3 hours after dose) drawn at each clinic attendance. Compartmental pharmacokinetic modeling was conducted using nonlinear mixed-effects modeling. One hundred twenty-three patients contributed 795 anti-Xa activities for pharmacokinetic modeling purposes. Both enoxaparin clearance and volume of distribution were increased during pregnancy. Simulations of once- versus twice-daily enoxaparin administration demonstrated that both dosing regimens would reach target 3-hour plasma concentrations throughout the duration of the pregnancy. When trough anti-Xa activity was simulated, both once- and twice-daily regimens exhibited an increase in trough anti-Xa activity with the progression of pregnancy. This is explained by the significant increase in volume of distribution observed during pregnancy. Conclusions— The half-life of enoxaparin is prolonged with the progression of pregnancy, and our work provides compelling evidence for prescribing once-daily enoxaparin for the treatment of antenatal venous thromboembolism. National and international guideline recommendations should be reconsidered.Keywords
This publication has 36 references indexed in Scilit:
- Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta‐analysis of the literatureJournal of Thrombosis and Haemostasis, 2012
- Prescribing without evidence – pregnancyBritish Journal of Clinical Pharmacology, 2012
- VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest, 2012
- Drugs Dispensed in Primary Care During PregnancyDrug Safety, 2010
- Where do we go now with low molecular weight heparin use in obstetric care?Journal of Thrombosis and Haemostasis, 2008
- Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacyBlood, 2005
- Pregnancy-Induced Changes in PharmacokineticsClinical Pharmacokinetics, 2005
- Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients: A Prospective Cohort StudyThrombosis Research, 2000
- Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancyInternational Journal of Gynecology & Obstetrics, 1992
- LOW-MOLECULAR-WEIGHT HEPARIN IN VEINOUS THROMBOSIS DURING PREGNANCYBritish Journal of Haematology, 1986